Literature DB >> 10832689

Spectrum of fungal keratitis at Wills Eye Hospital, Philadelphia, Pennsylvania.

M A Tanure1, E J Cohen, S Sudesh, C J Rapuano, P R Laibson.   

Abstract

PURPOSE: To report the spectrum of fungal keratitis at Wills Eye Hospital, Philadelphia.
METHODS: We reviewed the records of 24 cases of culture-positive fungal keratitis treated from January 1991 to March 1999 at Wills Eye Hospital. Risk factors, fungal identification, antifungal treatment, and outcomes were evaluated.
RESULTS: The study included 24 eyes (24 patients). Fourteen patients (58.3%) were female. The mean age was 59 years (range, 19-86 years). Predisposing factors included chronic ocular surface disease (41.7%), contact lens wear (29.2%), atopic disease (16.7%), topical steroid use (16.7%), and ocular trauma (8.3%). Early identification of fungal elements was achieved by staining of corneal scrapings in 18 cases (75%). Half of the cases (12 eyes) had corneal infections caused by yeast, and the other half by filamentous fungi. Candida albicans was the most commonly isolated organism (45.8%), followed by Fusarium sp (25%). Natamycin and amphotericin B were the topical antifungals most frequently used, while systemic treatment commonly used included fluconazole, ketoconazole, or itraconazole. Six patients (25%) had penetrating keratoplasty during the acute stage of infection. After a mean follow-up of nine months, 13 eyes (54.1%) had the best corrected visual acuity 20/100 or better.
CONCLUSIONS: In contrast to other studies from the northern United States, we found Fusarium sp the most commonly isolated filamentous fungus. In our series, C. albicans was the most frequent cause of fungal keratitis, and a past history of ocular trauma was uncommon.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10832689     DOI: 10.1097/00003226-200005000-00010

Source DB:  PubMed          Journal:  Cornea        ISSN: 0277-3740            Impact factor:   2.651


  76 in total

1.  Aspergillus keratitis following corneal foreign body.

Authors:  B Fahad; M McKellar; M Armstrong; D Denning; A Tullo
Journal:  Br J Ophthalmol       Date:  2004-06       Impact factor: 4.638

2.  Clinical characteristics and outcome of Candida keratitis.

Authors:  Regina L Sun; Dan B Jones; Kirk R Wilhelmus
Journal:  Am J Ophthalmol       Date:  2007-06       Impact factor: 5.258

3.  Diagnosis of fusariosis in urine cytology.

Authors:  Cheng-Chuan Su; Hui-Jine Hsu; Jiunn-Jong Wu; Chien-Wen Chou
Journal:  J Clin Pathol       Date:  2006-06-30       Impact factor: 3.411

4.  Therapeutic effect of 0.03% tacrolimus ointment for ocular graft versus host disease and vernal keratoconjunctivitis.

Authors:  Eun Hye Ryu; Joung Mok Kim; Pradnya M Laddha; Eui-Sang Chung; Tae-Young Chung
Journal:  Korean J Ophthalmol       Date:  2012-07-24

5.  [Persistent contact lens-associated keratitis].

Authors:  A Klingenstein; W J Mayer; J Rueping; C Miller; A Kampik; H Mino De Kaspar
Journal:  Ophthalmologe       Date:  2011-12       Impact factor: 1.059

6.  Current Thoughts in Fungal Keratitis: Diagnosis and Treatment.

Authors:  Zubair Ansari; Darlene Miller; Anat Galor
Journal:  Curr Fungal Infect Rep       Date:  2013-09-01

7.  Fusarium solani Activates Dectin-1 in Experimentally Induced Keratomycosis.

Authors:  Ling-Juan Xu; Li-Xin Xie
Journal:  Curr Med Sci       Date:  2018-03-15

Review 8.  Challenges in the Polyene- and Azole-Based Pharmacotherapy of Ocular Fungal Infections.

Authors:  Prit Lakhani; Akash Patil; Soumyajit Majumdar
Journal:  J Ocul Pharmacol Ther       Date:  2018-11-08       Impact factor: 2.671

9.  Curcumin inhibits angiogenesis by up-regulation of microRNA-1275 and microRNA-1246: a promising therapy for treatment of corneal neovascularization.

Authors:  Yanhui Bai; Weiqun Wang; Guangli Sun; Mingchang Zhang; Jingmin Dong
Journal:  Cell Prolif       Date:  2016-09-14       Impact factor: 6.831

Review 10.  Current perspectives on ophthalmic mycoses.

Authors:  Philip A Thomas
Journal:  Clin Microbiol Rev       Date:  2003-10       Impact factor: 26.132

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.